JP2006506041A - Ox40r結合剤 - Google Patents
Ox40r結合剤 Download PDFInfo
- Publication number
- JP2006506041A JP2006506041A JP2003580382A JP2003580382A JP2006506041A JP 2006506041 A JP2006506041 A JP 2006506041A JP 2003580382 A JP2003580382 A JP 2003580382A JP 2003580382 A JP2003580382 A JP 2003580382A JP 2006506041 A JP2006506041 A JP 2006506041A
- Authority
- JP
- Japan
- Prior art keywords
- ox40r
- protein
- binding agent
- ox40l
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 title claims abstract description 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 134
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 62
- 230000003993 interaction Effects 0.000 claims abstract description 39
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 24
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 16
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 107
- 102000004169 proteins and genes Human genes 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 45
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 31
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 27
- 102000051450 human TNFSF4 Human genes 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 239000000816 peptidomimetic Substances 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000012377 drug delivery Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 108050001049 Extracellular proteins Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 102000045341 human CCL5 Human genes 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 229940124447 delivery agent Drugs 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 abstract description 58
- 102000004473 OX40 Ligand Human genes 0.000 abstract description 57
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract description 11
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract description 9
- 230000005754 cellular signaling Effects 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 239000011324 bead Substances 0.000 description 26
- 238000003016 alphascreen Methods 0.000 description 25
- 238000003556 assay Methods 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- -1 ACT-4-L Proteins 0.000 description 20
- 102100021514 HLA class I histocompatibility antigen protein P5 Human genes 0.000 description 20
- 101000899151 Homo sapiens HLA class I histocompatibility antigen protein P5 Proteins 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 10
- 229960005314 suramin Drugs 0.000 description 10
- 108010090804 Streptavidin Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 101000764258 Mus musculus Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 125000003277 amino group Chemical class 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 239000002253 acid Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101800004196 Peptide P4 Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XFZYPCNLVHSQTG-UHFFFAOYSA-N 2,2,5,7,8-pentamethyl-3,4-dihydrochromene Chemical compound C1CC(C)(C)OC2=C(C)C(C)=CC(C)=C21 XFZYPCNLVHSQTG-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical class [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006786 activation induced cell death Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 238000012440 amplified luminescent proximity homogeneous assay Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000003050 experimental design method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007728 intracellular signaling mechanism Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical group OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000016412 positive regulation of cytokine production Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
a)i)本発明で述べられた化合物、細胞、および支持体の中から選択されるOX40R結合剤を構成する要素、
ii)OX40R細胞外領域を含むタンパク質、その表面にOX40R細胞外領域を発現する細胞系、およびOX40R細胞外領域を分泌する細胞系の中から選択されるOX40R部分を構成する要素、および
iii)OX40R−OX40L相互作用の阻害剤として試験される化合物の要素、を含むサンプルを形成するステップと、
b)要素(i)と(ii)との間の相互作用に対する化合物(iii)の効果を直接的または間接的に検出するステップと、
c)(b)において、(a)の要素の質および/または量の点で異なるサンプル間で検出された効果を比較するステップと
を含む、OX40R−OX40L相互作用を阻害する化合物の性質および活性度の判定のためのスクリーニング検査も開示する。
方法
タンパク質
ヒトOX40R−IgG1融合タンパク質については、以前に述べられている(ゴドフリー(Godfrey)ら、1994)。組換えタンパク質は、pCEP4(インビトロゲン(Invitrogen))をベースとする哺乳類の発現ベクターを構築して調製し、その中でヒトOX40Rの細胞外部分をコード化するcDNA(SWISSPROT Acc.番号P43489のアミノ酸1〜208)は、ヒトIgG1の定常部をコード化するcDNAの5’末端にインフレーム融合される(ヒンジ領域、CH2およびCH3;SWISSPROT Acc.番号P01857のアミノ酸98〜330)。組換えOX40R−IgG1は、OX40Rのシグナル配列のために分泌タンパク質として発現される。
アルファスクリーン(Alphascreen)TM修飾アクセプターおよび供与体ビーズを購入した(バイオシクンッルパッカード(Biosignal Packard)。OX40R−IgG1およびOX40L−CD8融合タンパク質をタンパク質A−接合アクセプタービーズ上に、ビオチン化抗CD8抗体の手段によってストレプトアビジン接合供与体ビーズ上に、それぞれ固定化した。
KD、IC50、およびEC50値は全てプリズム(Prism)(登録商標)ソフトウェア(グラフパッドソフトウェア(Graphpad Software))を使用して計算した。IC50値のKi値への転換は、チェング(Cheng)−プルソフ(Prusoff)方程式(チェング(Cheng)YCおよびプルソフ(Prusoff)WH、1973)を使用して実施した。
文献で既知のOX40L結合アッセイとしては、FACSベースの分析(テイラー(Taylor)Lら、2002)、またはビアコア(Biacore)TMベースの分析(アル−シャムカニ(Al−Shamkhani)Aら、1997)が挙げられる。これらの技術は高速大量処理スクリーニングには不適切であるので、ルミネッセンス酸素チャネリングイムノアッセイ(Luminescent Oxygen Channeling Immunoassay(LOCI;欧州特許第515194号明細書;ウルマン(Ullman)Eら、1994)をベースとする方法である、増幅ルミネッセンス近接均質アッセイスクリーン(Amplified Luminescent Proximity Homogeneous Assay Screen)(アルファスクリーン(Alphascreen)TM;パッカードバイオサイエンス(Packard Bioscience))と称される市販の技術を利用して、OX40R−OX40L相互作用に対するOX40L由来ペプチドの可能な阻害特性を確立するためのより効率的なシステムが創設された。
方法
ペプチド
エピトップ(Epytop)(フランス)によって、85〜97%の範囲の純度でペプチド(10〜31アミノ酸)を合成し、−20℃で凍結乾燥形態で保存した。使用前に、PBS中0.1mMのNaOHでペプチドを可溶化した。各ペプチドの名称、配列、およびヒトOX40L中の対応するアミノ酸を表IIIに示す。
最初の添加ステップ中に、5μL容積の様々な濃度の各ペプチドと共に、可溶性構成成分(OX40−IgG1、OX40L−CD8、およびビオチン化抗CD8抗体)をOX40Lとスラミンの競合アッセイ(図4)について既述した濃度で混合した。ストレプトアビジン供与体およびタンパク質Aアクセプタービーズを30分後に添加した。実施例1で述べたようにより短い発光波長520〜620nmと組み合わせた長い励起波長680nmで読み取る前に、プレートを暗中、室温で振盪して2時間インキュベートした。
前述のようにして蛍光消光アッセイを実施した(ゴラベク(Golabek)Aら、2000)。OX40R−IgG1(35μg)を500μLのPBS中に溶解し、スリットを5nmに設定した分光蛍光計(パーキンエルマー(Perkin Elmer)LS50B)を使用して、励起波長290nmで蛍光スペクトルを295〜420nmで記録した。次に15分間の平衡化後に、ヒトOX40R−IgG1の蛍光スペクトルを増大する濃度(5〜1000nM)のP5およびP5−1ペプチド存在下で記録した。336nmでの蛍光変化をペプチド濃度に対してプロットし、得られた曲線をプリズム(Prism)(登録商標)ソフトウェア(グラフパッド(GraphPad))で非線形回帰適合によって分析した。
タンパク質のアミノ酸51〜183に対応するヒトOX40L細胞外領域の配列に基づいて、一連の部分的に重なるペプチドをデザインした(図5A;表III)。この領域では、抗OX40L抗体を作るために、マウスOX40Lの配列に基づいて2つのぺプチドが以前デザインされている(ストゥーバー(Stuber)Eおよびストローバー(Strober)W、1996)。
アル−シャムカニ(Al Shamkhani)Aら、J Biol Chem、272:5275〜5282、1997
アルザーニ(Alzani)Rら、Biochemistry、34:6344〜6350、1995
バンサル−パカラ(Bansal−Pakala)Pら、Nat Med、7:907〜912、2001
ボドマー(Bodmer)JLら、Trends Bioch Sci、27:19〜26、2002
チェン(Chen)Aら、Immunity、11:689〜698、1999
チェング(Cheng)YCおよびプルソフ(Prusoff)WH、Biochem Pharmacol、22:3099〜3108、1973
クレランド(Cleland)JLら、Curr Opin Biotechnol、12:212〜219、2001
コクラン(Cochran)Aら、Curr Opin Chem Biol、5:654〜659、2001
コールマン(Coleman)RAら、Drug Disc Today、6:1116〜1125、2001
コンスタンス(Constans)A、The Scientist、16:37、2002
ドゥガーティ(Dougherty)DA、Curr Opin Chem Biol、4:645〜652、2000
ゴドフリー(Godfrey)WRら、J Exp Med、180:757〜762、1994
ゴラベク(Golabek)Aら、Biophys J、79:1008〜1015、2000
ゴレビオウスキー(Golebiowski)Aら、Curr Opin Drug Discov Devel、4:428〜434、2001
グラベンスタイン(Gravestein)Lおよびボルスト(Borst)J、Semin Immunol、10:423〜434、1998
グレイ(Gray)PWら、Proc Natl Acad Sci、87:7380〜7384、1990
ヒギンズ(Higgins)LMら、J Immunol、162:486〜493、1999
フルビー(Hruby)VJおよびバルセ(Balse)PM、Curr Med Chem、7:945〜970、2000
イムラ(Imura)Aら、Blood、89:2951〜2958、1997
キム(Kim)HOおよびカーン(Kahn)M、Comb Chem High Throughput Screen、3:167〜183、2000
コップ(Kopf)Mら、Immunity、11:699〜708、1999
コタニ(Kotani)Aら、Immunol Lett、84:1〜7、2002
クレーマー−ペコール(Kraemer−Pecore)CMら、Cur Opin Chem Biol、5:690〜695、2001
ロウ(Lowe)CRら、J Biochem Biophys Methods、49:561〜574、2001
ルオ(Luo)Bおよびプレストウィッチ(Prestwich)GD、ExpOpin Ther Patents、11:1395〜1410、2001
マクライズ(Makrides)SC、Protein Expr Purif、17:183〜202、1999
ミウラ(Miura)Sら、Mol Cell Biol、11:1313〜1325、1991
ムラタ(Murata)Kら、J Exp Med、191:365〜374、2000
マーフィー(Murphy)LRら、Protein Eng、13:149〜152、2000
ノハラ(Nohara)Cら、J Immunol、166:2108〜2115、2001
ピライ(Pillai)Oおよびパンチャングヌラ(Panchagnula)R、Cur Opin Chem Biol、5:447〜451、2001
ピッピグ(Pippig)SDら、J Immunol、163:6520〜6529、1999
ラネー(Ranney)DF、Biochem Pharmacol、59:105〜114、2000
ロゴブ(Rogov)SIおよびネクラソブ(Nekrasov)AN、Protein Eng、14:459〜463、2001
ソーヤー(Sawyer)TK、「Structure Based Drug Design」より、ヴィーラパンディアン(Veerapandian)P編、マーセル・デッカー・インコーポレイテッド(Marcel Dekker Inc)、557〜663ページ、1997
ストゥーバー(Stuber)Eおよびストローバー(Strober)W、J Exp Med、183:979〜989、1996
テイラー(Taylor)Lおよびシュワルツ(Schwarz)H、J Imm Methods、255:67〜72、2001
テイラー(Taylor)Lら、J Leuk Biol、72:522〜529、2002
ツカダ(Tsukada)Nら、Blood、95:2434〜2439、2000
ウルマン(Ullman)Eら、Proc Natl Acad Sci、91:5426〜5430、1994
ヴィラン(Villain)Mら、Chem Biol、8:673〜9、2001
ワインバーグ(Weinberg)Aら、Nat Med、2:183〜189、1996
ワインバーグ(Weinberg)Aら、J Immunol、162:1818〜1826、1999
ワインバーグ(Weinberg)A、Trends Immunol、23:102〜109、2002
ヨシオカ(Yoshioka)Yら、Eur J Immunol、30:2815〜2823、2000
Claims (34)
- ヒトOX40Lのアミノ酸94〜124(配列番号:6)のペプチド配列に対応するOX40R結合剤。
- 1つ以上のアミノ酸が欠落し、ヒトOX40Lのアミノ酸107〜111(配列番号:13)を含む、アミノ酸94〜124(配列番号:6)に対応するペプチド配列からなるヒトOX40Lのペプチド配列であるOX40R結合剤。
- 5〜10個のアミノ酸を有するヒトOX40Lのペプチド配列である、請求項2に記載のOX40R結合剤。
- ヒトOX40Lの107〜116(配列番号:8)、または107〜111(配列番号:13)に対応する配列を有するペプチドである、請求項3に記載のOX40R結合剤。
- 1つ以上のアミノ酸が保存的に置換されている、請求項1〜4のいずれか1項に記載のペプチドの活性変異体であるOX40R結合剤。
- 請求項1〜5のいずれか1項に記載のアミノ酸配列と、ヒトOX40L(配列番号:1)以外のタンパク質配列に属するアミノ酸配列とを含む、融合ポリぺプチドまたはペプチドであるOX40R結合剤。
- 融合ポリぺプチドまたはペプチドが、膜結合タンパク質、膜結合タンパク質の細胞外領域、免疫グロブリン定常部、多量体化領域、細胞外タンパク質、シグナルペプチド含有タンパク質、搬出シグナル含有タンパク質の1つ以上のタンパク質配列に属するアミノ酸配列を含む、請求項6に記載のOX40R結合剤。
- 請求項1〜7のいずれか1項に記載のOX40R結合剤の活性画分、前駆物質、塩、または誘導体であるOX40R結合剤。
- 請求項4に記載のOX40R結合剤の配列および/または構造に基づいてデザインされた、ペプチド、ペプチドミメティック、または非ペプチドミメティックであるOX40R結合剤。
- 分子が、放射性標識、ビオチン、蛍光標識、細胞毒性作用物質、およびドラッグデリバリー作用物質の中から選択される、請求項1〜9のいずれか1項に記載のOX40R結合剤の活性接合体または複合体である、OX40R結合剤。
- 請求項1〜7のいずれか1項に記載のOX40R結合剤をコードする核酸。
- 請求項11に記載の核酸によってコードされたOX40R結合剤の発現を可能にする、ウィルスまたはプラスミド起源のベクター。
- 請求項12に記載の発現ベクターで形質転換されている、原核または真核宿主細胞。
- 請求項13に記載の細胞内で実質的に富化された分離安定細胞系。
- OX40R結合剤が細胞膜上で分泌または発現される、請求項14に記載の細胞系。
- 請求項13〜15のいずれか1項に記載の細胞を培養するステップと、前記結合剤を収集するステップとを含む、請求項1〜7のいずれか1項に記載のOX40R結合剤を製造する方法。
- 請求項1〜10のいずれか1項に記載のOX40R結合剤の精製品。
- 請求項1〜10のいずれか1項に記載のOX40R結合剤の薬物としての使用。
- 請求項1〜10のいずれか1項に記載のOX40R結合剤のヒトOX40L拮抗剤としての使用。
- 請求項1〜10のいずれか1項に記載のOX40R結合剤のヒトRANTES拮抗剤としての使用。
- 自己免疫疾患、炎症、または感染症の予防および/または治療のための請求項1〜10のいずれか1項に記載のOX40R結合剤の医薬組成物中の活性成分としての使用。
- 請求項1〜10のいずれか1項に記載のOX40R結合剤を活性成分として含む、CD4+T細胞に関する疾患の予防および/または治療のための医薬組成物。
- 薬学上許容可能なキャリア、賦形剤、安定剤、および/または希釈剤と組み合わせた、請求項22に記載の医薬組成物。
- CD4+T細胞に関する疾患が、移植自己免疫疾患、炎症、または感染症である、請求項22または23に記載の医薬組成物。
- 膜結合または可溶性タンパク質としてのOX40Rタンパク質の細胞外領域の検出のための請求項1〜10のいずれか1項に記載のOX40R結合剤、または請求項14または15に記載の細胞の使用。
- 活性化CD4+T細胞の検出のための請求項1〜10のいずれか1項に記載のOX40R結合剤、または請求項14または15に記載の細胞の使用。
- 膜結合または可溶性タンパク質としてのOX40R細胞外領域の、または活性化CD4+T細胞の検出、精製、および/または濃縮のための支持体であって、請求項1〜7のいずれか1項に記載のOX40R結合剤を固定化形態で有する支持体。
- サンプルを請求項27に記載の支持体、または請求項14または15に記載の細胞に接触させるステップを含む、前記サンプル中の膜結合または可溶性タンパク質としてのOX40R細胞外領域の、または活性化CD4+T細胞の検出、精製、および/または濃縮方法。
- 減少したまたは増大したCD4+T細胞または可溶性OX40Rタンパク質の存在に関連した病状を診断するために使用される、請求項28に記載の方法。
- 請求項1〜10のいずれか1項に記載のOX40R結合剤または請求項14または15に記載の細胞を投与するステップを含む、自己免疫疾患、炎症、または感染症の予防および/または治療方法。
- a)i)請求項1〜10に記載の化合物、請求項14または15に記載の細胞、および請求項27に記載の支持体の中から選択されるOX40R結合剤を構成する要素、
ii)OX40Rの細胞外領域を含むタンパク質、その表面にOX40Rの細胞外領域を発現する細胞系、およびOX40Rの細胞外領域を分泌する細胞系の中から選択されるOX40R部分を構成する要素、および
iii)OX40R−OX40L相互作用モジュレーターとして試験される化合物
の要素を含むサンプルを形成するステップと、
b)要素(i)と(ii)との間の相互作用に対する化合物(iii)の効果を直接的または間接的に検出するステップと、
c)(b)において、(a)の要素の質および/または量の点で異なるサンプル間で検出された効果を比較するステップと
を含む、OX40R−OX40L相互作用を調節する化合物の性質および活性度の判定のためのスクリーニング検査。 - 請求項1〜10に記載のOX40R結合剤、請求項14または15に記載の細胞、または請求項27に記載の支持体を含む、OX40Rタンパク質の細胞外領域または活性化CD4+T細胞を検出するためのキット。
- 患者から得られたサンプル中の減少したまたは増大したCD4+T細胞または可溶性OX40Rタンパク質の存在による病状の診断のための請求項32に記載のキット。
- 異なるタグ配列を有する融合タンパク質として膜結合性タンパク質の細胞外部分とタンパク質リガンドとを含む、タンパク質リガンドと膜結合性タンパク質との相互作用を阻害する化合物をスクリーニングするためのキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02100334 | 2002-04-03 | ||
PCT/EP2003/050089 WO2003082919A2 (en) | 2002-04-03 | 2003-04-02 | Ox40r binding agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006506041A true JP2006506041A (ja) | 2006-02-23 |
JP4426315B2 JP4426315B2 (ja) | 2010-03-03 |
Family
ID=28459562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003580382A Expired - Fee Related JP4426315B2 (ja) | 2002-04-03 | 2003-04-02 | Ox40r結合剤 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7758852B2 (ja) |
EP (1) | EP1492813B1 (ja) |
JP (1) | JP4426315B2 (ja) |
AR (1) | AR039231A1 (ja) |
AT (1) | ATE557036T1 (ja) |
AU (1) | AU2003240761B2 (ja) |
CA (1) | CA2480694A1 (ja) |
ES (1) | ES2387767T3 (ja) |
IL (1) | IL164376A0 (ja) |
WO (1) | WO2003082919A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016002820A1 (ja) * | 2014-06-30 | 2016-01-07 | 国立大学法人東北大学 | 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004281817B2 (en) | 2003-10-17 | 2010-07-22 | Baylor College Of Medicine | A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis |
AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
AR057253A1 (es) | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
US20110008368A1 (en) * | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
EP2038303A2 (en) * | 2006-06-21 | 2009-03-25 | Genentech, Inc. | Crystal structure of ox40l and ox40l complexed with ox40 receptor |
US9347947B2 (en) * | 2009-03-12 | 2016-05-24 | Siemens Healthcare Diagnostics Inc. | Immunoassays employing non-particulate chemiluminescent reagent |
SG187945A1 (en) | 2010-08-23 | 2013-03-28 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ox40抗体およびそれを使用する方法 |
US8999380B2 (en) * | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US10696946B2 (en) | 2013-02-22 | 2020-06-30 | The Board Of Trustees Of The University Of Illinois | T-REG cell expansion |
US20140294792A1 (en) * | 2013-02-22 | 2014-10-02 | The Board Of Trustees Of The University Of Illinois | T-REG Cell Expansion |
CN106999577B (zh) | 2014-07-16 | 2021-12-21 | 特兰斯吉恩股份有限公司 | 溶瘤病毒和免疫检查点调节因子组合 |
EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
AU2016215175B2 (en) | 2015-02-06 | 2021-09-16 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
EP4015537A1 (en) | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
AU2016362697B2 (en) | 2015-12-03 | 2018-07-12 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of STING |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
LT3440076T (lt) | 2016-04-07 | 2022-09-26 | Glaxosmithkline Intellectual Property Development Limited | Heterocikliniai amidai, naudingi kaip baltymų moduliatoriai |
CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
WO2018015879A1 (en) | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
EP3494140A1 (en) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos and anti-pd-1 antibody combination therapy |
WO2018071405A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
CN110234342A (zh) | 2016-12-01 | 2019-09-13 | 葛兰素史密斯克莱知识产权发展有限公司 | 组合疗法 |
AU2017368923A1 (en) | 2016-12-01 | 2019-06-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
WO2018157163A1 (en) * | 2017-02-27 | 2018-08-30 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
EP3635011A1 (en) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
CN110831971A (zh) | 2017-06-09 | 2020-02-21 | 葛兰素史克知识产权开发有限公司 | 用icos激动剂和ox40激动剂治疗癌症的组合疗法 |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
EP3692034A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
CN113924317A (zh) | 2019-02-01 | 2022-01-11 | 葛兰素史克知识产权开发有限公司 | 贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症 |
JP2022539178A (ja) | 2019-06-26 | 2022-09-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Il1rap結合タンパク質 |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
EP4034562A2 (en) | 2019-09-27 | 2022-08-03 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins |
BR112022014562A2 (pt) | 2020-01-28 | 2022-09-13 | Glaxosmithkline Ip Dev Ltd | Tratamentos de combinação, usos e métodos dos mesmos |
JP2024509529A (ja) | 2021-03-02 | 2024-03-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Dnmt1阻害剤としての置換ピリジン |
WO2022208353A1 (en) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106197A (en) * | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US6602856B1 (en) * | 1995-01-17 | 2003-08-05 | J. Mark Quillan | Antagonists of alpha-melanocyte stimulating hormone and methods based thereon |
US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
EP1171626A4 (en) * | 1999-03-26 | 2002-10-30 | Human Genome Sciences Inc | FIFTY HUMAN SECRETED PROTEINS |
US6872519B1 (en) * | 1999-04-27 | 2005-03-29 | Mirus Bio Corporation | In vitro process for selecting phage resistant to blood inactivation |
WO2001057251A2 (en) * | 2000-02-04 | 2001-08-09 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
AU2000239309A1 (en) | 2000-03-29 | 2001-10-08 | Dgi Biotechnologies Llc | Insulin and igf-1 receptor agonists and antagonists |
-
2002
- 2002-04-03 IL IL16437602A patent/IL164376A0/xx unknown
-
2003
- 2003-04-02 AU AU2003240761A patent/AU2003240761B2/en not_active Ceased
- 2003-04-02 WO PCT/EP2003/050089 patent/WO2003082919A2/en active Application Filing
- 2003-04-02 AT AT03730172T patent/ATE557036T1/de active
- 2003-04-02 CA CA002480694A patent/CA2480694A1/en not_active Abandoned
- 2003-04-02 JP JP2003580382A patent/JP4426315B2/ja not_active Expired - Fee Related
- 2003-04-02 AR ARP030101155A patent/AR039231A1/es not_active Application Discontinuation
- 2003-04-02 EP EP03730172A patent/EP1492813B1/en not_active Expired - Lifetime
- 2003-04-02 US US10/510,015 patent/US7758852B2/en not_active Expired - Fee Related
- 2003-04-02 ES ES03730172T patent/ES2387767T3/es not_active Expired - Lifetime
-
2009
- 2009-11-24 US US12/624,534 patent/US7858765B2/en not_active Expired - Fee Related
-
2010
- 2010-11-23 US US12/952,226 patent/US20110086057A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016002820A1 (ja) * | 2014-06-30 | 2016-01-07 | 国立大学法人東北大学 | 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬 |
Also Published As
Publication number | Publication date |
---|---|
CA2480694A1 (en) | 2003-10-09 |
ATE557036T1 (de) | 2012-05-15 |
JP4426315B2 (ja) | 2010-03-03 |
ES2387767T3 (es) | 2012-10-01 |
IL164376A0 (en) | 2005-12-18 |
US7758852B2 (en) | 2010-07-20 |
US20070009964A1 (en) | 2007-01-11 |
WO2003082919A3 (en) | 2004-02-05 |
AR039231A1 (es) | 2005-02-09 |
AU2003240761A1 (en) | 2003-10-13 |
EP1492813B1 (en) | 2012-05-09 |
US7858765B2 (en) | 2010-12-28 |
WO2003082919A2 (en) | 2003-10-09 |
US20100136628A1 (en) | 2010-06-03 |
AU2003240761B2 (en) | 2009-04-23 |
US20110086057A1 (en) | 2011-04-14 |
EP1492813A2 (en) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4426315B2 (ja) | Ox40r結合剤 | |
JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
US7947805B2 (en) | BCMA polypeptides and uses thereof | |
AU743490B2 (en) | NTN-2 member of TNF ligand family | |
CA2301173C (en) | Cysteine rich receptors-train | |
KR20010006405A (ko) | 오스테오프로테게린 결합 단백질 및 수용체 | |
US20090286956A1 (en) | DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof | |
JP2003534813A (ja) | シスチンノットポリペプチド:cloaked−2分子およびその使用 | |
PL211786B1 (pl) | Zastosowanie przeciwciała oraz polipeptydu | |
JP2002533134A (ja) | ペプチドグリカン認識タンパク質 | |
JP2001157593A (ja) | 哺乳動物ケモカインccf18およびレセプターcckr3 | |
JP2003528611A (ja) | β様糖タンパク質ホルモンのポリペプチドおよびヘテロ二量体 | |
JP2004500125A (ja) | アンギオペプチンによって確認される機能性受容体としてのGPCRx11を発現し、アゴニストおよびアンタゴニストのスクリーニングに役立つ組換え細胞系 | |
WO1999026977A1 (en) | Novel receptors opg-2 | |
AU748167B2 (en) | Novel nucleic acid and polypeptide | |
JP4623342B2 (ja) | Il−1エータのdna及びポリペプチド | |
KR20120036947A (ko) | 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법 | |
JP2002114800A (ja) | アポトーシス抑制ペプチド | |
JP2006524982A (ja) | 新規ifnガンマ様ポリペプチド | |
JP2007523591A (ja) | 新規フィブリン様ポリペプチド | |
JP2003079378A (ja) | 新規なジンクフィンガータンパク質ezi及びその遺伝子 | |
JP2004500105A (ja) | T細胞シグナル伝達のアポリポタンパク質−a−1調節 | |
JP2003079376A (ja) | 新規なジンクフィンガータンパク質ezi及びその遺伝子 | |
JP2007523592A (ja) | 新規前駆脂肪細胞因子−1様ポリペプチド | |
JP2002138099A (ja) | アポトーシス抑制ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060327 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090911 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091110 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091210 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |